CAMP4 THERAPEUTICS CORPORATION
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsCAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to upregulate gene expression for genetic diseases, with its lead candidate CMP-002 for SYNGAP1 disorder entering Phase 1/2 trials.
What they do
CAMP4 uses its proprietary RAP Platform to identify regulatory RNAs (regRNAs) that control gene expression, then designs antisense oligonucleotide (ASO) candidates to amplify mRNA and restore healthy protein levels. The company's primary focus is on central nervous system diseases, specifically haploinsufficient disorders. Its lead candidate, CMP-002, is an intrathecally delivered ASO designed to increase SYNGAP1 gene expression for SYNGAP1-related disorder, a severe developmental and epileptic encephalopathy. The company also has a research collaboration with GlaxoSmithKline to extend the platform beyond CNS.
Revenue drivers
- Research and collaboration revenue — Revenue is currently derived from research collaborations, particularly the agreement with GlaxoSmithKline; reported revenue was $795,000 in Q3 2025, $348,000 in Q4 2025, $1.3M in Q1 2026, and $1.8M in Q2 2026, but the company has no approved products and no product sales.
Recent performance
For the quarter ended June 30, 2026, the company reported revenue of $1.8 million, up from $348,000 in the prior quarter. Net loss for Q2 2026 was $33.5 million, compared to $12.6 million in Q2 2025, driven largely by a $20.9 million non-cash loss from a change in fair value of a derivative tranche liability. Cash and cash equivalents were $86.4 million as of June 30, 2026, down from $109.5 million at year-end 2025. Fiscal year 2025 revenue was $3.5 million with a net loss of $80.4 million. Research and development expenses for Q2 2026 were $10.8 million, compared to $10.3 million in the same period of 2025.
Strategy
CAMP4's stated strategy is to advance CMP-002 into a global Phase 1/2 clinical trial for SYNGAP1 disorder, with regulatory clearance already received in Australia and Argentina and additional filings submitted in the EU and UK. The company also intends to expand its discovery pipeline in other developmental and epileptic encephalopathies and leverage its GlaxoSmithKline partnership to validate the RAP Platform outside the CNS. Management emphasizes the potential of CMP-002 to be the first disease-modifying therapy for SYNGAP1, given no approved treatments exist. The company secured $50.1 million in a second closing of a private placement to extend cash runway through the end of 2028.
Risks
- Clinical-stage with no approved products — CMP-002 has not yet entered clinical trials; failure in preclinical or clinical studies would halt development and the company has no revenue from product sales.
- Significant operating losses and need for capital — The company has incurred losses since inception and expects to continue; while current cash is expected to fund through end of 2028, additional funding will be required to complete development and commercialization.
- Regulatory approval uncertainties — CMP-002 requires regulatory clearances in multiple jurisdictions; even with clearance in Australia and Argentina, approvals in the EU and UK and eventual marketing approval are uncertain.
- Reliance on intellectual property and collaborations — The company depends on licensed intellectual property and its collaboration with GlaxoSmithKline; failure to maintain these agreements could impair operations.
Outlook
Management expects to initiate the Phase 1/2 clinical trial of CMP-002 in the fourth quarter of 2026, following regulatory clearances in Australia and Argentina. The company plans to activate additional trial sites in the EU and UK and will host a Virtual Analyst Day on September 28, 2026, to provide updates on clinical trial design and early pipeline. CAMP4 believes its current cash will fund planned activities through the end of 2028.